Core Viewpoint - Ansh Biotechnology Co., Ltd. has transitioned its IPO status to "inquired" on the Sci-Tech Innovation Board, indicating progress in its public offering process [1] Group 1: Company Overview - Ansh Biotechnology is an innovative biopharmaceutical company that has entered the commercialization phase, focusing on diseases with significant unmet clinical needs, particularly in oncology [1] - The company aims to provide high-quality innovative anti-tumor drugs through efficient independent research and development, enhancing the quality of life for patients [1] Group 2: IPO Details - The IPO application for Ansh Biotechnology was accepted on September 26 [1] - The company plans to raise 2.45 billion yuan through the IPO, which will be allocated to new drug research and development projects as well as to supplement working capital [1]

New Listings - From September 22 to September 28, one company was listed on the Shanghai Stock Exchange main board, and three companies were listed on the Shenzhen Stock Exchange ChiNext [2] - YouSheng Co., Ltd. is a professional manufacturer of aluminum alloy automotive parts, focusing on lightweight automotive components to enhance the range of electric vehicles and improve fuel efficiency for gasoline vehicles. On its first trading day, the stock price rose by 71.48%, closing at 66.31 CNY per share on September 29, an increase of 43.03% from the issue price of 46.36 CNY, with a total market capitalization of approximately 12.8 billion CNY [3] ChiNext Listings - Shanghai Jianfa Zhixin Medical Technology Group Co., Ltd. engages in direct sales, distribution, and centralized management of hospital consumables. On its first trading day, the stock price surged by 418.58%, closing at 34.12 CNY per share on September 29, a rise of 383.97% from the issue price of 7.05 CNY, with a total market capitalization of around 14.4 billion CNY [4] - Suzhou Huichuan United Power System Co., Ltd. focuses on the R&D, production, sales, and service of core components for electric drive systems and power systems for electric vehicles. The stock price increased by 147.60% on its first day, closing at 32.77 CNY per share on September 29, up 162.58% from the issue price of 12.48 CNY, with a total market capitalization of approximately 78.8 billion CNY [4] - Beijing Wuchuang Ruitong Electric Equipment Co., Ltd. specializes in the R&D, production, and sales of smart distribution equipment. The stock price rose by 190.76% on its first trading day, closing at 58.78 CNY per share on September 29, an increase of 179.90% from the issue price of 21.00 CNY, with a total market capitalization of about 6.5 billion CNY [5] Companies Passing Review - From September 22 to September 28, two companies passed the review on the Shanghai Stock Exchange Sci-Tech Innovation Board, and one company passed the review on the Shenzhen Stock Exchange ChiNext [6] - BaiAo SaiTu is a preclinical CRO and biotechnology company that provides innovative animal models and preclinical drug development services based on its proprietary gene editing technology [7] - MoEr Thread focuses on the R&D, design, and sales of GPUs and related products, having successfully launched four generations of GPU architecture [7] Companies Submitting IPO Applications - One company submitted an IPO application on the Shanghai Stock Exchange Sci-Tech Innovation Board, and one company submitted an application on the Shenzhen Stock Exchange ChiNext from September 22 to September 28 [10] - Anshi Biotechnology is an innovative biopharmaceutical company focusing on oncology and other diseases with significant unmet clinical needs. The company plans to issue no more than 76.0043 million shares, aiming to raise 2.45 billion CNY for new drug R&D and working capital [12] - Zhongsu Co., Ltd. specializes in the R&D, production, and sales of modified engineering plastics, with applications in consumer electronics, energy storage, automotive, and home appliances. The company plans to issue no more than 12.3329 million shares, seeking to raise 645 million CNY for various projects [14] Companies with Terminated Review - From September 22 to September 28, no companies had their listing reviews terminated on either the Shanghai Stock Exchange or the Shenzhen Stock Exchange [16]

Core Viewpoint - The article discusses the impact of the U.S. tariff policies on global trade and the subsequent response from China, highlighting the opportunities for domestic industries to replace imports in various sectors due to increased tariffs on U.S. goods [1] Group 1: Import Substitution Opportunities - The sectors with significant import substitution potential in A-shares include chips, photoresists, scientific instruments, medical devices, and aerospace equipment [1] - A total of 50 stocks have been identified as having strong potential for import substitution based on performance and institutional interest [1][6] Group 2: High Import Dependency Categories - Key categories with high import dependency in China include electronics (semiconductor components/devices, optical components), medical devices, machinery (measuring instruments, machine tools, cutting tools), aerospace equipment, and chemical products [4] - In 2022, China's imports from the U.S. in electronic machinery, agricultural products, chemicals, and energy exceeded 150 billion yuan, indicating a significant reliance on U.S. imports [5] Group 3: Market Size and Growth Potential - The global market for analog chips is valued at $79.4 billion, with China's demand accounting for 30% to 40%, translating to a market space of approximately 240 billion yuan [6] - The medical device market in China has a high dependency on imports, with 70% of high-end equipment (e.g., MRI, CT machines) sourced from companies like GE and Siemens, representing a market space worth several hundred billion yuan [6] Group 4: R&D Investment and Innovation - The average R&D investment ratio for the top 50 import substitution stocks exceeds 21%, significantly higher than the A-share average [9] - Notable companies include Longxin Technology with an R&D investment ratio of 105.34%, and BeiGene with over 14.1 billion yuan invested in R&D, focusing on innovative cancer treatments [9][10] Group 5: Stock Performance and Growth Projections - Among the top 50 stocks, companies like SMIC, Haiguang Information, and Heng Rui Medicine have market capitalizations exceeding 100 billion yuan, primarily in semiconductor equipment, AI chips, and innovative pharmaceuticals [7] - The average projected net profit growth for these companies is close to 69%, with several stocks expected to double their profits this year [12]